Pfizer’s IGF-1 Inhibitor Leads Pack In Phase III For NSCLC

Pfizer's CP-751,871 for metastatic non-small cell lung cancer recently became the first insulin-like growth factor 1 receptor inhibitor to enter Phase III trials, as the class gains popularity and strength